YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
In late September and early October 2026, Travere Therapeutics reported new FILSPARI® (sparsentan) data across IgA nephropathy and FSGS at ASN Kidney Week and secured extended U.S. patent protection for FILSPARI use in these rare kidney di…
Two-year SPARTAN data show 75% complete proteinuria remission and eGFR stabilization with first-line use of FILSPARI in IgAN FILSPARI demonstrated approximately 3x higher complete proteinuria remission rates and 75% lower kidney failure ra…
SAN DIEGO, September 23, 2026--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, t…
Travere Therapeutics (NasdaqGM:TVTX) announced a planned CEO and President transition effective December 1, 2026. Dr. Eric Dube will step down from his roles as CEO and President as part of the scheduled leadership change. Bradley L. Campb…
Travere Therapeutics has delivered a very large share price gain over the past few years, which naturally puts the focus on what investors are paying for its sales today. With the stock now reflecting years of optimism, the immediate quest…
Eric Dube, Ph.D., has decided to step down as President and Chief Executive Officer in December Following Eight Years of Exemplary Leadership Bradley L. Campbell to be Appointed President and CEO Effective December 1, 2026 SAN DIEGO, Septe…
SAN DIEGO, September 17, 2026--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at…
SAN DIEGO, September 11, 2026--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on September 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 16 new employees…
Biotech name Travere Therapeutics is not profitable yet but a turnaround may be around the corner as the stock hovers near a buy zone. Continue Reading
Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average. Continue Reading
Travere Therapeutics is Friday's IBD Stock Of The Day. As the Filspari story gets "sweeter," shares are clearing a fresh buy point. Continue Reading
These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months. Continue Reading
SAN DIEGO, August 12, 2026--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on August 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 12 new employees, cons…
Earlier this week, Travere Therapeutics reported Q2 2026 results showing revenue rising to US$169.58 million from US$114.45 million a year earlier, alongside a wider net loss of US$34.8 million versus US$12.76 million. The quarter highligh…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Travere Therapeutics (TVTX) drew investor attention on 4 August 2026 after reporting second quart…
Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike. Continue Reading
Ligand stock bounded out of a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike. Continue Reading
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Travere Therapeutics stock has delivered a very strong 341.0% return over the past five years, and…
The Dow Jones hit a new high thanks to Nvidia, but Google, SpaceX and AMD weighed on the Nasdaq. Sandisk, Western Digital fell late. Continue Reading
(RTTNews) - The following biotech stocks reached a 52-week high on August 5, 2026, primarily driven by positive quarterly reports. Bioventus Inc. (BVS) Bioventus is a medical device company that focuses on technology for pain management an…
The Dow Jones hit a new high thanks to Nvidia, but Google, SpaceX and AMD weighed on the Nasdaq. Sandisk, Western Digital fell late. Continue Reading
SAN DIEGO, August 05, 2026--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: Canaccord Genuity's 46th Annual Growth Conferen…
This article first appeared on GuruFocus. Total US Net Product Sales: $161.4 million in Q2 2026, reflecting strong sequential and year-over-year growth. FILSPARI US Net Product Sales: $141.1 million, up approximately 96% year over year, dr…
Earnings Call Insights: Travere Therapeutics (TVTX) Q2 2026 MANAGEMENT VIEW * "The second quarter was exceptional." (President, CEO & Director Eric Dube) "This was the first quarter with FILSPARI commercially available across both IgA neph…
For the quarter ended June 2026, Travere Therapeutics (TVTX) reported revenue of $169.58 million, up 48.2% over the same period last year. EPS came in at -$0.37, compared to -$0.14 in the year-ago quarter. The reported revenue represents a…
Travere Therapeutics (TVTX) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items…
Strong FSGS launch and continued IgAN growth drive robust FILSPARI demand; 2,012 new PSFs received during the second quarter U.S. net product sales of FILSPARI grew 96% year-over-year to $141 million Enrollment of pegtibatinase Phase 3 HAR…
Use the IBD Stock Checklist to separate the wheat from the chaff in the stock market, specifically in the red-hot biotech sector. Continue Reading
SAN DIEGO, July 28, 2026--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. The Compan…
LGND stock has risen more than 56.5% so far in 2026. Ligand doesn't make drugs; it forks over funding in exchange for Big Pharma royalties. Continue Reading
Novartis NVS announced that the FDA has granted traditional approval to Fabhalta (iptacopan) for slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. This tradit…
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareho…
SAN DIEGO, July 10, 2026--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 41,6…
SHANGHAI, July 7, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeuti…
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s. Previous close: $26.99. An 81% gain, ov…
William Rote, Ph.D., chief research officer plans to retire in early 2027 Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Company's research or…